Q3 EPS Estimates for Haemonetics Lifted by Zacks Research

Haemonetics Corporation (NYSE:HAE) – Research analysts at Zacks Research boosted their Q3 2027 earnings per share (EPS) estimates for Haemonetics in a report issued on Tuesday, March 24th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $1.42 for the quarter, up from their previous estimate of $1.41. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2027 earnings at $1.35 EPS.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The firm had revenue of $338.97 million for the quarter, compared to analysts’ expectations of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The company’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS.

Other equities analysts also recently issued research reports about the stock. Citigroup decreased their target price on shares of Haemonetics from $75.00 to $70.00 and set a “neutral” rating for the company in a research note on Wednesday, March 11th. JPMorgan Chase & Co. upped their price target on Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research note on Friday, December 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 29th. Robert W. Baird set a $81.00 price objective on Haemonetics in a research note on Friday, February 6th. Finally, Barrington Research set a $94.00 target price on Haemonetics in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and an average price target of $83.89.

Haemonetics Trading Down 0.7%

NYSE:HAE opened at $55.54 on Thursday. Haemonetics has a one year low of $47.31 and a one year high of $87.32. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15. The company’s 50-day simple moving average is $62.63 and its 200 day simple moving average is $64.89. The firm has a market capitalization of $2.58 billion, a P/E ratio of 15.30, a PEG ratio of 1.17 and a beta of 0.28.

Institutional Investors Weigh In On Haemonetics

Institutional investors have recently made changes to their positions in the company. Rockefeller Capital Management L.P. increased its position in shares of Haemonetics by 10,875.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 878 shares of the medical instruments supplier’s stock valued at $70,000 after acquiring an additional 870 shares in the last quarter. World Investment Advisors bought a new position in Haemonetics in the 4th quarter valued at approximately $246,000. Virtu Financial LLC bought a new position in Haemonetics in the 4th quarter valued at approximately $452,000. Mercer Global Advisors Inc. ADV purchased a new stake in Haemonetics during the 4th quarter valued at $509,000. Finally, EP Wealth Advisors LLC purchased a new stake in Haemonetics during the 4th quarter valued at $288,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.